28 crossroads magazine The healthtech track of the renowned startup accel- erator programme Fit 4 Start, open to both local and international participants, raises companies’ regula- tory awareness from day one. It helps them take re- quirements into account from an early stage, rather than discovering them once the solution is finalised and having to redevelop all or part of their solution to achieve the necessary compliance. A second programme, Fit 4 Innovation – Healthtech Market, provides healthtech startups established in Luxembourg with access to specialised expert consult- ants who can help them define their regulatory roadm- ap for an EU market launch. Luxembourg’s strategic investment Another priority for the Luxembourg government is to foster innovation by facilitating companies’ access to high-quality standardised health data in a secure, federated and interoperable manner. Health data use cases such as the patient cohorts of the National Cen- tre of Excellence in Research on Parkinson’s disease and those set up under the international project focus- ing on personalised medicine of specific inflammato- ry diseases, demonstrate Luxembourg’s strong capa- bilities in setting up key data processing environments. Deriving insights and developing new applications from large amounts of health data requires consider- able computing power. Companies can rely on Lux- embourg’s business-oriented high-performance com- puter MeluXina, which is soon to be complemented by a second supercomputer purpose-built for AI and a quantum computer. “These are major investments, also supported by Eu- ropean funding,” underlines Dr Liners. “They testify to Luxembourg’s commitment to becoming by 2030 one of the leaders in the sovereign data economy, in Europe but also globally. By catalysing innovation, these investments will also contribute to positioning the country as a European healthtech hub for the de- velopment, evaluation and adoption of digital health technologies in the European market.” BEYOND THE BAND-AID © Qatar Financial Centre © pharma.be crossroads magazine